Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone
Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone have?
Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone has 77 citations in the OpenAlex counts ScholarIQ stores.
When was Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone published?
Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone has 2015 year in the ScholarIQ index.
What is the open-access status of Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone?
Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone has closed oa status in the ScholarIQ index.
What is the DOI of Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone?
The DOI for Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone is on the source record.
What is the PMID of Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone?
The PMID for Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone is on the source record.
What is the OpenAlex record for Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone?
The OpenAlex for Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone is on the source record.